A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study

BACKGROUND: Prognosis remains poor after progression on first-line chemotherapy for colorectal adenocarcinoma, and inactivation of the EGFR pathway with monoclonal antibodies is an effective treatment strategy in selected patients with metastatic disease. Lapatinib is an oral EGFR and HER-2 dual tyr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Frank, Daniel, Jumonville, Alcee, LoConte, Noelle K, Schelman, William R, Mulkerin, Daniel, Lubner, Sam, Richter, Katie, Winterle, Natalie, Wims, Mary Beth, Dietrich, Leah, Winkler, J. Mitchell, Volk, Michael, Kim, KyungMann, Holen, Kyle D.
Format: Artigo
Idioma:Inglês
Publicat: Pioneer Bioscience Publishing Company 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397648/
https://ncbi.nlm.nih.gov/pubmed/22811876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2011.049
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars